Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351732 | 0.86 | TSHR (0.65) | TSHRLMNAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL5357724 | 0.86 | TSHR (0.58) | TSHRLMNAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL10660024 | 0.80 | — | — | |
| Dimethyl Succinate SCHEMBL10213 | 0.79 | TSHR (1.00) | TSHRLMNAKDM4EALDH1A1HSD17B10 | |
| Dimethyl Succinate SCHEMBL28054469 | 0.79 | TSHR (1.00) | TSHRLMNAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL30082500 | 0.79 | MCL1 (0.33) | — | |
| SCHEMBL9173199 | 0.76 | TSHR (0.62) | TSHRLMNAKDM4EALDH1A1HSD17B10 | |
| Dimethyl Succinate SCHEMBL7778900 | 0.76 | TSHR (0.93) | TSHRLMNAKDM4EALDH1A1HSD17B10 | |
| Dimethyl Succinate SCHEMBL16798755 | 0.76 | TSHR (0.93) | TSHRLMNAKDM4EALDH1A1HSD17B10 | |
| Dimethyl Succinate SCHEMBL31389405 | 0.76 | TSHR (0.93) | TSHRLMNAKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256230-A1 | 1-BUTANE ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES AND THE USE THEREOF | SCHEBO BIOTECH AG (DE) | 2010-10-07 | — | — | US | disclosed |
| US-20070238781-A1 | Compounds for the modulation of the glykolysis-enzyme-and/or of the transaminase-complex | EIGENBRODT ERICH | 2007-10-11 | — | — | US | disclosed |
| US-7223784-B2 | Compounds for the modulation of the glycolysis enzyme and/or transaminase complex | ScheBo® Biotech AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20040266873-A1 | 1-butane acid derivatives pharmaceutical compositions containing said derivatives and the use thereof | SCHEBO. BIOTECH AG (DE) | 2004-12-30 | — | — | US | disclosed |
| US-20040152772-A1 | 1-butyric acid derivatives and the use thereof | WARBURG GLYCOMED GMBH (DE) | 2004-08-05 | — | — | US | disclosed |
| EP-1404322-A2 | 1-BUTANE ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES AND THE USE THEREOF | Schebo Biotech AG (DE) | 2004-04-07 | — | — | EP | disclosed |
| EP-1377291-A2 | 1-BUTYRIC ACID DERIVATIVES SUCH AS CARBOMETHOXYPROPIONYL CYANIDE OR LEFLUNOMIDE DERIVATIVES, AND THE THERAPEUTIC USE THEREOF | Protagen AG (DE) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002072527-A2 | 1-BUTYRIC ACID DERIVATIVES SUCH AS CARBOMETHOXYPROPIONYL CYANIDE OR LEFLUNOMIDE DERIVATIVES, AND THE THERAPEUTIC USE THEREOF | PROTAGEN AKTIENGESELLSCHAFT (DE) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002072534-A2 | 1-BUTANE ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES AND THE USE THEREOF | EIGENBRODT ERICH (DE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152772-A1 | 1-butyric acid derivatives and the use thereof | GABRB1, BTN3A1, NFATC1 | TSHR 1620/4885LMNA 4533/4885KDM4E 3649/4885 |
| US-20040266873-A1 | 1-butane acid derivatives pharmaceutical compositions containing said derivatives and the use thereof | CYP11B2, CYC1, GOT2 | TSHR 4385/4885LMNA 869/4885KDM4E 3839/4885 |
| US-20070238781-A1 | Compounds for the modulation of the glykolysis-enzyme-and/or of the transaminase-complex | PC, GOT1, PCK1 | TSHR 3366/4885LMNA 2467/4885KDM4E 3602/4885 |
| US-20100256230-A1 | 1-BUTANE ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAID DERIVATIVES AND THE USE THEREOF | CYP11B2, CYC1, CYP11B1 | TSHR 4237/4885LMNA 787/4885KDM4E 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.